BeDia Genomics NIMoTest®
We are proud to introduce the NIMoTest® RHD test by BeDia Genomics to the US market. Designed to address critical public health needs in prenatal care, this cutting-edge assay offers reliable, non-invasive genotyping of fetal RHD directly from maternal blood.
By leveraging advanced real-time PCR technology, NIMoTest® provides laboratories with a streamlined, highly accurate solution for predicting fetal Rh status early in pregnancy.
Key Features
Non-Invasive Precision
Detects fetal RHD genotypes utilizing cell-free fetal DNA found in maternal blood samples.
Fully Automated via the AIO System
Pair NIMoTest® with our AIO (All-In-One) system for a completely optimized, turnkey workflow. This powerful combination minimizes hands-on time, reduces contamination risks, and maximizes throughput.
Dual-Exon Certainty
Utilizes multiplex real-time chemistry for the duplex detection of exons 5 and 7 of the RHD gene. This robust format delivers an exceptional 100% diagnostic sensitivity and 98.8% diagnostic specificity, minimizing undetermined results and the need for patient re-testing
Certified Quality
Manufactured under a strict Quality Management System (QMS) with ISO 13485 certification, ensuring standard-setting batch consistency and regulatory compliance.